racemetirosine has been researched along with Basal Ganglia Diseases in 1 studies
alpha-Methyltyrosine: An inhibitor of the enzyme TYROSINE 3-MONOOXYGENASE, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with PHEOCHROMOCYTOMA. (Martindale, The Extra Pharmacopoeia, 30th ed)
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wolkin, A | 1 |
| Duncan, E | 1 |
| Sanfilipo, M | 1 |
| Wieland, S | 1 |
| Cooper, TB | 1 |
| Rotrosen, J | 1 |
1 other study available for racemetirosine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function.
Topics: Adult; alpha-Methyltyrosine; Antipsychotic Agents; Basal Ganglia Diseases; Dopamine; Drug Resistance | 1994 |